Monte Rosa Therapeutics, Inc.

NasdaqGS:GLUE 주식 보고서

시가총액: US$513.6m

Monte Rosa Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

Monte Rosa Therapeutics 의 총 주주 지분은 $205.5M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $315.1M 및 $109.6M 입니다.

주요 정보

0%

부채 비율

US$0

부채

이자 보상 비율n/a
현금US$242.19m
주식US$205.46m
총 부채US$109.62m
총 자산US$315.08m

최근 재무 상태 업데이트

Recent updates

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts

Nov 12
News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash

Oct 28

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Sep 23
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Mar 20
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

Sep 29
Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

May 01
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

Jan 16
We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Oct 01
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment

Sep 06

We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely

Jun 17
We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Mar 04
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn

Sep 24
We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn

재무 상태 분석

단기부채: GLUE 의 단기 자산 ( $251.2M )이 단기 부채( $41.6M ).

장기 부채: GLUE 의 단기 자산( $251.2M )이 장기 부채( $68.0M ).


부채 대 자본 내역 및 분석

부채 수준: GLUE 부채가 없습니다.

부채 감소: GLUE 5년 전에 부채가 없었습니다.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: GLUE 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: GLUE 8.1 1.9 8.1 % 매년.


건강한 기업 발견하기